We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
The current 0RN3 market cap is 78.09B. The company's latest EPS is JPY 91.0423 and P/E is 0.54.
| Year End March 30 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| JPY (¥) | JPY (¥) | JPY (¥) | JPY (¥) | JPY (¥) | |
| Total Revenue | 3.35T | 3.28T | 3.61T | 4.05T | 4.28T |
| Operating Income | 70.72B | 275.69B | 438.73B | 479.78B | 220.41B |
| Net Income | 44.24B | 376.01B | 230.06B | 317.02B | 144.07B |
| Year End March 30 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| JPY (¥) | JPY (¥) | JPY (¥) | JPY (¥) | JPY (¥) | |
| Total Assets | 12.82T | 12.91T | 13.18T | 13.96T | 15.11T |
| Total Liabilities | 8.09T | 7.74T | 7.49T | 7.6T | 7.83T |
| Total Equity | 4.73T | 5.18T | 5.68T | 6.35T | 7.27T |
| Year End March 30 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| JPY (¥) | JPY (¥) | JPY (¥) | JPY (¥) | JPY (¥) | |
| Operating | 669.75B | 1.01T | 1.12T | 977.16B | 716.34B |
| Investing | 292.12B | 393.53B | -198.13B | -607.1B | -463.86B |
| Financing | -1.01T | -1.09T | -1.07T | -709.15B | -354.42B |
| Market Cap | 78.09B |
| Price to Earnings Ratio | 0.54 |
| Price to Sales Ratio | 0.02 |
| Price to Cash Ratio | 0.17 |
| Price to Book Ratio | 0.01 |
| Dividend Yield | - |
| Shares Outstanding | 1.58B |
| Average Volume (1 week) | 0 |
| Average Volume (1 Month) | 0 |
| 52 Week Change | 0.00% |
| 52 Week High | 49.35 |
| 52 Week Low | 49.35 |
| Spread (Intraday) | 0 (0%) |
| Company Name | Takeda Pharmaceutical Co Ltd |
| Address |
4-1-1 doshomachi chuo, tokyo 540-8645 |
| Website | https://www.takeda.co.jp |
| Industry | pharmaceutical diversified (H2) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
